Literature DB >> 16760909

Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation.

Q Sun1, Z-H Liu, S Ji, J Chen, Z Tang, C Zeng, C Zheng, L-S Li.   

Abstract

This study was performed to investigate the clinical and pathologic features of C4d-positive steroid-resistant acute rejection (AR) at different phases after renal transplantation. Fifty-six kidney allograft recipients with C4d-positive AR were divided into three groups, very early rejection (VER, occurring < or =14 days following transplantation, n=28), early rejection (ER, occurring 15-180 days following transplantation, n=5), and late rejection (LR, occurring >180 days following transplantation, n=23). Clinical and pathological features were evaluated. Significantly more patients in the ER and LR groups were associated with a reduction or withdrawal of immunosuppressants. More patients in the ER and LR groups experienced a significant (>3 g/l) decrease in serum albumin (80% ER, 91.3% LR, 7.1% VER, P<0.001) and a decrease in hemoglobin (>1 g/dl) (80, 100 vs 17.9%, P<0.001). Most VER patients reported a fever and had very rapid graft dysfunction requiring dialysis. Significantly more patients (87%) had interstitial fibrosis and tubular atrophy in the LR group compared with the other groups and 13% had transplant glomerulopathy. Most cases of VER were reversed with tacrolimus and mycophenolate mofetil treatment, with or without immunoadsorption, with a 1-year survival rate of 96.4%, compared with only 60 and 52.2% in the ER and LR groups. In conclusion, C4d-positive steroid-resistant AR at different time points is associated with unique clinico-histopathological manifestations requiring distinct treatment strategies. Late episodes are usually associated with significantly reduced serum albumin and hemoglobin levels and a poorer outcome. A more specialized treatment protocol should be established for these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760909     DOI: 10.1038/sj.ki.5001552

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation.

Authors:  Julio Pascual; Milagros D Samaniego; José R Torrealba; Jon S Odorico; Arjang Djamali; Yolanda T Becker; Barbara Voss; Glen E Leverson; Stuart J Knechtle; Hans W Sollinger; John D Pirsch
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

2.  Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.

Authors:  James H Lan; David Gjertson; Ying Zheng; Stephanie Clark; Elaine F Reed; Michael J Cecka
Journal:  Am J Transplant       Date:  2018-05-09       Impact factor: 8.086

3.  Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy.

Authors:  Eric A Elster; Jason S Hawksworth; Orlena Cheng; David B Leeser; Michael Ring; Douglas K Tadaki; David E Kleiner; John S Eberhardt; Trevor S Brown; Roslyn B Mannon
Journal:  J Mol Diagn       Date:  2010-08-05       Impact factor: 5.568

Review 4.  [Chronic rejection: Differences and similarities in various solid organ transplants].

Authors:  H Suhling; J Gottlieb; C Bara; R Taubert; E Jäckel; M Schiffer; J H Bräsen
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

5.  Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection.

Authors:  Qiquan Sun; Zhihong Liu; Jinsong Chen; Huiping Chen; Jiqiu Wen; Dongrui Cheng; Leishi Li
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

6.  Molecular phenotypes of acute rejection predict kidney graft prognosis.

Authors:  Ondrej Viklicky; Petra Hribova; Hans-Dieter Volk; Janka Slatinska; Jan Petrasek; Stepan Bandur; Eva Honsova; Petra Reinke
Journal:  J Am Soc Nephrol       Date:  2009-09-24       Impact factor: 10.121

7.  Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.

Authors:  Meghan H Pearl; Anjali B Nayak; Robert B Ettenger; Dechu Puliyanda; Miguel Fernando Palma Diaz; Qiuheng Zhang; Elaine F Reed; Eileen W Tsai
Journal:  Pediatr Nephrol       Date:  2016-04-05       Impact factor: 3.714

Review 8.  Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis.

Authors:  Yu-Gang Zhao; Bing-Yi Shi; Ye-Yong Qian; Hong-Wei Bai; Li Xiao; Xiu-Yun He
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

Review 9.  Antibody-mediated rejection after kidney transplantation in children; therapy challenges and future potential treatments.

Authors:  Massimiliano Bertacchi; Paloma Parvex; Jean Villard
Journal:  Clin Transplant       Date:  2022-02-16       Impact factor: 3.456

10.  Improving arteriovenous fistula patency: Transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation.

Authors:  Mark G MacAskill; David G Watson; Marie-Ann Ewart; Roger Wadsworth; Andrew Jackson; Emma Aitken; Graeme MacKenzie; David Kingsmore; Susan Currie; Paul Coats
Journal:  Vascul Pharmacol       Date:  2015-04-10       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.